Leadership at Diagnosis: Quarterbacking the Path to Precision Care
Watch Video
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
Why Regular MRD Testing Matters for Ovarian Cancer Patients
Read Article
-
How MRD Testing Supports Ovarian Cancer Patients: Holly’s Story
Read Article
-
Signatera Results Patient Guide
Read More
-
Dr. James Duke’s Head & Neck Cancer Story
Read Article
-
Latitude Workflow
Watch Video
-
Latitude Explainer Overview
Watch Video
-
Ketch Study Data 1 Sheet
Read More
-
Anj’s Breast Cancer Story
Read Article
-
Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer
Ketch et al. JCO PO 2025
Read More
-
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients With Resected Stages I to III Colon Ca
Cohen et al. Annals of Surgery 2025
Read More
-
MRD Testing vs. Traditional Cancer Monitoring: What’s the Difference?
Read Article
-
Understanding Hereditary Cancer Risks in Ovarian Cancer
Read Article
-
How MRD Testing Helps Monitor Ovarian Cancer Recurrence
Read Article
-
Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing
Watch Video
-
Meet Anj, Breast Cancer Survivor and Signatera Patient
Watch Video
-
Post-Treatment H&N Cancer Surveillance with ctDNA
Read More
-
Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma
Zhang Y, et al. Biomedicines. 2025
Read More
-
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Ca
Abdelrahim M, et al. JCO Preci Oncol. 2025
Read More
-
Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy
Kim J, et al. Cancers 2025
Read More
-
Loading More...
